What We're Hearing at hearUcan

Hearing health has spent most of its modern history telling one story: how to manage a condition that couldn't be reversed, with devices that helped you hide it, policies that slowly expanded access, and data that kept proving how many people weren't getting help. This edition crosses a different kind of line. A therapy now exists that may reverse hearing loss at its genetic root — the first time that's been true. An invisible cochlear implant is at the finish line of its clinical trial. And a dataset from 125,000 consumer wearables has just produced the largest tinnitus study in history.

My name is Mark Parkinson and I am Co-founder of hearUcan. I wore hearing aids for 12 years and now have bi-lateral cochlear implants. We founded the hearUcan comminity to help those with hearing loss navigate what can be a very confusing and frustrating journey. Family members, friends, work colleagues, and the stranger at the cash register, are all on this journey with you. Let’s get started……

On April 28, 2026, the FDA approved Otarmeni by Regeneron — the first gene therapy ever cleared to treat hearing loss. It targets severe-to-profound sensorineural hearing loss caused by biallelic OTOF gene mutations, delivered as a one-time surgical injection into the cochlea. In the pivotal pediatric trial, 80% of evaluable participants showed meaningful hearing improvement.

Why it matters: This is not a hearing aid or an implant. It's a therapy that may reverse hearing loss for a defined genetic population — the first time that sentence has been true. For families navigating a new pediatric diagnosis, a clinician can now say something that has never been said before: we may be able to reverse this.

For audiologists: Genetic counseling literacy just became a clinical competency. Which patients should be referred for OTOF testing? What's the conversation when gene therapy is an option alongside cochlear implant candidacy?

For the CI market: OTOF-variant patients were a natural CI candidate group. They now have an alternative. This is the first regulatory proof of concept that hearing loss can be reversed, not just managed.

Read more →

Envoy Medical announced all 56 participants in the U.S. pivotal trial of the Acclaim cochlear implant have completed activation. Unlike every CI on the market, the Acclaim has no external processor, no visible hardware, and nothing to remove for sleep or swimming. It uses the ear's own anatomy as its sensor. Completion of all activations clears the path for 12-month outcome data and an eventual PMA filing.

Why it matters: Stigma around visible devices is among the top three cited reasons people delay or reject treatment. The Acclaim eliminates that variable entirely. For working adults who have avoided cochlear implant conversations because of how they'd look in professional settings — this is a different conversation. If outcomes match current external-processor CI systems, the stigma barrier for implant adoption shifts significantly.

Read more →

A new 8-year ARIC-NCS cohort study (n=3,602; 22% Black adults; ages 68–89) confirmed moderate-to-severe hearing loss raises dementia risk 66–71% — consistently across racial groups. But the study surfaced something the field hasn't seen clearly before: moderate-to-severe hearing loss was linked to approximately 2.3× higher mortality risk specifically in Black participants — a relationship absent in White participants.

Why it matters: The racial mortality gap is new, urgent, and not explained by hearing loss severity alone. For audiologists: equitable access to hearing care is now a life-and-death clinical priority for a measurable patient population, not just an equity value. For health systems and payers: outreach for Black adults at earlier stages of hearing loss isn't just good equity practice — it's linked to survival outcomes.

Read more →

Both Medicare hearing bills remain parked in committee with no markup scheduled. H.R. 500 has 26 cosponsors and approximately 1% enactment odds — reintroduced every Congress since 2015 with no movement past referral. MAAIA (H.R. 2757 / S. 1996) is the more compelling story: the Warren/Paul/Grassley Senate coalition is rare bipartisan support, and all three major audiology associations endorse it. Any committee hearing scheduled for MAAIA would be the first meaningful signal to watch.

Nothing has moved. The 1983 occupational noise standard is unchanged. The only 2025 Federal Register noise activity was routine paperwork renewals and a July interpretive letter — none of which alter a single decibel of exposure limits. The current administration's deregulatory agenda actively moves in the opposite direction.

What this means: The permissible exposure limit (90 dBA) and action level (85 dBA) are where they were when Thriller was number one. For blue-collar workers in construction, manufacturing, and agriculture — the regulatory backstop isn't coming. Hearing protection habits and employer wellness programs are the only lever available right now.

Apple is no longer a future player in hearing health data. It's a present one. The AirPods Pro 2 Hearing Aid Feature (FDA cleared, September 2024) is globally available; an independent study found 86.5% audiometric accuracy in 5.5 minutes. A March 2026 BMC Public Health paper from 125,252 Apple Hearing Study participants found 30.8% of U.S. adults report tinnitus — the largest such study in history using consumer wearable data. A companion analysis linked tinnitus severity to lower Apple Watch heart rate variability — an objective biomarker for a condition that has always been self-reported.

Apple's most important number: 40% of study participants hadn't had a hearing test in 10+ years. That's the most credible mass-market access gap figure in existence.

For manufacturers: Apple is redefining what consumer hearing health engagement looks like before anyone walks into a clinic. For audiologists: AirPods Pro 2 self-tests will show up in patient conversations — knowing their accuracy and limitations is now a clinical need.